As Biotechnology businesses, Cellectis S.A. (NASDAQ:CLLS) and Motif Bio plc (NASDAQ:MTFB), are affected by contrast. This especially applies to their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis S.A.	25.47M	28.85	82.53M	-2.11	0.00
Motif Bio plc	N/A	0.00	22.87M	-2.02	0.00

Table 1 highlights Cellectis S.A. and Motif Bio plc’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides Cellectis S.A. and Motif Bio plc’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
Cellectis S.A.	-324.03%	-23%	-18.8%
Motif Bio plc	0.00%	0%	0%

Analyst Ratings

The Ratings and Recommendations for Cellectis S.A. and Motif Bio plc are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Cellectis S.A.	0	1	0	2.00
Motif Bio plc	0	0	0	0.00

Cellectis S.A.’s consensus price target is $25, while its potential upside is 43.27%.

Institutional and Insider Ownership

Cellectis S.A. and Motif Bio plc has shares held by institutional investors as follows: 29.4% and 7.36%.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cellectis S.A.	-12.03%	-27.86%	-25.47%	-35.88%	-21.71%	-33.55%
Motif Bio plc	-9.72%	-12.49%	-26.94%	-37.05%	-34.34%	-39.87%

For the past year Cellectis S.A. was less bearish than Motif Bio plc.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.